{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:48:09Z","timestamp":1741153689405,"version":"3.38.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le SIDA et les H\u00e9patites virales\u2014Maladies Infectieuses Emergentes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir. Given the widespread use of dolutegravir, further studies of S147G are required.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We consulted the HIV-1 resistance databases of French laboratories to identify all cases of S147G emergence. We collected immunological and virological parameters, history of treatment and INSTI resistance mutations. Mann\u2013Whitney and Fisher\u2019s exact tests were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We retrospectively identified 88 cases of S147G selection, from 2015 to 2022, in 22 laboratories. The most frequent HIV-1 subtypes were Clade B (55.7%) and CRF02_AG (21.6%). At the time of resistance genotyping, the median viral load was 5860\u2005copies\/mL (IQR 1011\u201324\u200a\u200a525) and the median CD4 cell count was 412\u2005cells\/mm3 (228\u2013560). S147G emerged on dolutegravir (48%), elvitegravir (36%) and raltegravir (10%) treatments. S147G was associated with a larger median number of other INSTI mutations on dolutegravir than on elvitegravir [3.0 (2.0\u20134.0) versus 2.0 (1.0\u20132.0); P\u200a=\u200a0.0002] and was never observed with Q148H or G118R. On dolutegravir, S147G was associated principally with T97A (62%), N155H (59%), E138K (50%), L74I\/M (38%) and Q148R (33%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this French study, S147G emerged principally in patients on dolutegravir regimens, in association with up to five other INSTI resistance mutations. This accumulation of mutations suggests a replicative advantage on HIV strains under dolutegravir selection pressure, suggesting that caution is required when interpreting dolutegravir resistance in the presence of such S147G resistance patterns, even in patients prescribed dolutegravir twice daily.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae457","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T15:04:27Z","timestamp":1735571067000},"page":"692-696","source":"Crossref","is-referenced-by-count":0,"title":["Major role of dolutegravir in the emergence of the S147G integrase resistance mutation"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3723-4142","authenticated-orcid":false,"given":"Marc","family":"Wirden","sequence":"first","affiliation":[{"name":"Department of Virology, Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , 83 Boulevard de l'H\u00f4pital 39, F-75013 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-0010","authenticated-orcid":false,"given":"Basma","family":"Abdi","sequence":"additional","affiliation":[{"name":"Department of Virology, Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , 83 Boulevard de l'H\u00f4pital 39, F-75013 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-250X","authenticated-orcid":false,"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"Department of Virology, AP-HP, CHU Saint Antoine, INSERM, Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR-S 1136 , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-4621","authenticated-orcid":false,"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Department of Virology, INSERM U941, AP-HP, H\u00f4pital Saint-Louis, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"De Monte","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU de Nice , Nice ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Montes","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU Montpellier, Univ Montpellier , F-34295 Montpellier ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Pallier","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU Paul Brousse , Villejuif ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantxika","family":"Bellecave","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU de Bordeaux, Univ. Bordeaux, CNRS UMR 5234 , F-33076 Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Bouvier-Alias","sequence":"additional","affiliation":[{"name":"Department of Virology, CHU Henri Mondor , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5844","authenticated-orcid":false,"given":"Stephanie","family":"Raymond","sequence":"additional","affiliation":[{"name":"Department of Virology, INSERM UMR 1291, CHU Toulouse Purpan , F-31300 Toulouse ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[{"name":"Department of Virology, University Hospitals of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Department of Virology, Universit\u00e9 de Paris INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Department of Virology, Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , 83 Boulevard de l'H\u00f4pital 39, F-75013 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Department of Virology, Universit\u00e9 de Paris INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , F-75018 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevieve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Department of Virology, Sorbonne Universit\u00e9, INSERM, UMR-S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix , 83 Boulevard de l'H\u00f4pital 39, F-75013 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"2025030423054289200_dkae457-B1","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/jmv.25564","article-title":"Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na\u00efve individuals","volume":"91","author":"Margot","year":"2019","journal-title":"J Med Virol"},{"key":"2025030423054289200_dkae457-B2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/jac\/dkad101","article-title":"Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings","volume":"78","author":"Armenia","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054289200_dkae457-B3","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054289200_dkae457-B4","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1097\/QAD.0000000000001920","article-title":"Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana","volume":"32","author":"Seatla","year":"2018","journal-title":"AIDS Lond Engl"},{"key":"2025030423054289200_dkae457-B5","doi-asserted-by":"publisher","first-page":"19749","DOI":"10.7448\/IAS.17.4.19749","article-title":"New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy","volume":"17","author":"Carganico","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2025030423054289200_dkae457-B6","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/jac\/dkab193","article-title":"Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey","volume":"76","author":"Marcelin","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054289200_dkae457-B7","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025030423054289200_dkae457-B8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3851\/IMP3033","article-title":"Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients","volume":"21","author":"Naeger","year":"2016","journal-title":"Antivir Ther"},{"key":"2025030423054289200_dkae457-B9","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial","volume":"69","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025030423054289200_dkae457-B10","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/QAD.0000000000003288","article-title":"High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy","volume":"36","author":"Huik","year":"2022","journal-title":"AIDS Lond Engl"},{"key":"2025030423054289200_dkae457-B11","doi-asserted-by":"publisher","first-page":"ofy221","DOI":"10.1093\/ofid\/ofy221","article-title":"Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir","volume":"5","author":"George","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2025030423054289200_dkae457-B12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"2025030423054289200_dkae457-B13","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment emergent dolutegravir resistance mutations in individuals na\u00efve to HIV-1 integrase inhibitors: a rapid scoping review","volume":"15","author":"Tao","year":"2023","journal-title":"Viruses"},{"key":"2025030423054289200_dkae457-B14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir Ther"},{"key":"2025030423054289200_dkae457-B15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/692\/61296304\/dkae457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/692\/61296304\/dkae457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:05:49Z","timestamp":1741129549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/692\/7934848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,30]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae457","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,30]]}}}